Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GARDASIL in Healthy Females in India
NCT00733122Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Oct 2009
- Primary completion
- Oct 2013
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Merck & Co. Primary endpoint: Percentage of subjects who seroconvert to each of HPV 6, 11, 16, 18 at Month 36. Planned start Oct 2009; status: withdrawn.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00733122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00733122.